Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) traded down 9.8% on Wednesday . The stock traded as low as $0.28 and last traded at $0.32. 1,052,204 shares were traded during mid-day trading, an increase of 33% from the average session volume of 791,155 shares. The stock had previously closed at $0.36.

Several analysts recently weighed in on the company. B. Riley restated a “buy” rating and issued a $2.30 price objective on shares of Cytori Therapeutics in a report on Monday, May 15th. Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a report on Saturday, May 13th. Zacks Investment Research downgraded Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine downgraded Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

The stock’s market capitalization is $11.42 million. The firm’s 50 day moving average is $0.41 and its 200-day moving average is $1.03.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 450.34% and a negative return on equity of 202.62%. The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. During the same quarter last year, the business earned ($0.43) earnings per share. The business’s revenue was down 18.2% compared to the same quarter last year. Analysts anticipate that Cytori Therapeutics Inc will post ($0.60) EPS for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 99.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 874,896 shares of the biotechnology company’s stock after acquiring an additional 435,217 shares during the quarter. Cytori Therapeutics accounts for approximately 1.1% of Perkins Capital Management Inc.’s investment portfolio, making the stock its 28th biggest position. Perkins Capital Management Inc. owned 2.69% of Cytori Therapeutics worth $962,000 at the end of the most recent quarter. 11.82% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.